Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 81 SaxendaⓇ has rapidly grown value market share, but market development efforts are required to expand the market Despite strong SaxendaⓇ growth, US obesity care market remains small at USD ~740 million Novo Nordisk is investing in overcoming the barriers preventing effective obesity care Current state Key initiatives SaxendaⓇ Other branded AOM Generic AOM TRX market share mUSD/value market share 100% 800 7% Mindset 80% 600 43% 60% 82% 400 40% Few prescribers engaged 200 50% 20% 0% Limited patient Volume Value access AOM: Anti-obesity medication; TRx: Total prescriptions Source: IQVIA NPA and NSP moving annual total through February 2018 changing diabetes® Acute weight loss focus with SaxendaⓇ stay- time ~5 months Advocate for chronic treatment through partnerships Less than 3,000 physicians write ≥10 AOM prescriptions per month Only 2 in 5 of ~95 million adults with obesity have access to reimbursed medication Launch obesity educator programme Obtain Medicare coverage through support of "Treat and Reduce Obesity Act" novo nordisk

View entire presentation